In that study the addition of bevacizumab to capecitabine did not extend the progression-free survival of patients with refractory disease as compared with capecitabine monotherapy.
At this dose and schedule DNR, delayed disease progression by 8.1 days in the previously characterized T-ALL xenograft ALL-16, and when added to the VXL platform (VXLD) extended the progression delay of ALL-31 from 26.4– to 41.0 days (data not shown).
Paclitaxel, one of the most commonly used cancer chemotherapeutic drugs, effectively extends the progression-free survival of breast, lung, and ovarian cancer patients.
By extending the progression-free survival in patients with advanced NSCLC, bevacizumab-based therapy is favorable from the perspective of society by reducing the societal losses associated with this devastating disease.
Subsequently we elaborate and extend the learning progression of scientific explanation based on the PTDR framework.
As mentioned in Methods, in this work we reduced the concentration from 7.5 mM to 1 mM in order to extend the time of progression of symptoms.
From our studies, we conclude that antiretroviral treatment strategies initiated after 2 years postinfection are not beneficial to extend the time to progression to AIDS.
Several clinical trials have shown that ZOL may improve survival and extend the time to progression and/or exert an antitumour effect in cancer patients.
In addition, when used as maintenance therapy after the use of DNA-damaging chemotherapy, olaparib can significantly extend the time to progression of high-grade serous ovarian cancer (Ledermann et al, 2011), a disease where tumours are characterized by a relatively high frequency of HR gene mutations (TCGA, 2011).
In this work, we have extended the T2DM progression model presented by de Gaetano et al. by including specific IL-1β effects on β-cell turnover and function based on available ex vivo observations.
Direct evidence on the effects of targeted agents on bone metastases is currently limited to a few studies, which suggest that TKIs can extend the mean time to progression of existing bone lesions and reduce formation of new bone lesions2,76.
